

## 衛生福利部疾病管制署 函

機關地址：10050台北市中正區林森南路6號  
承辦人：許家瑜  
電話：23959825#3784  
電子郵件：cylia1029@cdc.gov.tw

100

台北市中正區忠孝東路二段100號10樓-4

受文者：社團法人台灣感染管制學會

發文日期：中華民國107年9月6日

發文字號：疾管防字第1070005990A號

速別：普通件

密等及解密條件或保密期限：

附件：107年腸病毒國際研討會海報

主旨：為促進國際腸病毒研究成果與防治經驗分享，本署與財團法人國家衛生研究院合作舉辦「腸病毒國際研討會」(Lessons Learned: 20th Anniversary of Enterovirus A71 Epidemic of 1998 in Taiwan)，請惠予轉知所屬會員踴躍參加，請查照。

說明：

一、我國自民國87年首度發生腸病毒71型大流行以後，多年來持續精進疫情監視、防治策略及臨床醫療，20年來累積可觀之研究成果及防治經驗，惟迄今腸病毒71型仍持續對我國及鄰近東南亞國家、中國大陸帶來危害，2014年美國發生大規模腸病毒D68型疫情，亦對其防疫與醫療體系造成相當衝擊，顯示腸病毒的威脅為全球不容忽視的問題，國際間有必要就研究發展、診治經驗及防治策略等層面進行交流分享。

二、旨揭研討會將於本（107）年9月28至9月29日間假財團法人張榮發基金會國際會議中心（台北市中正區中山南路11號 11樓，1101會議室）舉辦，議題包含腸病毒之致病機轉、監測與防治、臨床醫療處置及疫苗開發等，並安排國內外腸病毒領域之專家共同分享與討論，以促進各領域人員之交流及合作機會。

裝



三、請轉知並鼓勵所屬會員踴躍參加，參加者須進行線上報名（網址：<https://eva71.nhri.org.tw/index.php>），免繳報名費用。本研討會業已申請公務人員終身學習時數認證積分，另台灣內科醫學會、臺灣感染症醫學會、臺灣醫學會、臺灣兒科醫學會、臺灣兒童感染症醫學會、台灣兒童急診醫學會、社團法人台灣感染管制學會、中華民國護理師護士公會全國聯合會等相關學分刻正申請中。

正本：台灣內科醫學會、臺灣感染症醫學會、臺灣醫學會、臺灣兒科醫學會、社團法人台灣兒童感染症醫學會、社團法人台灣感染管制學會、中華民國護理師護士公會全國聯合會、台灣兒童急診醫學會

副本：

署長周志浩

訂

線



# Lessons Learned: 20th Anniversary of Enterovirus A71 Epidemic of 1998 in Taiwan

Date: September 28-29, 2018

Venue: Chang Yung-Fa International Convention Center, 1101 Conference Room

(張榮發國際會議中心 1101 會議室：台北市中正區中山南路 11 號 11 樓)

Adviser: Ministry of Health and Welfare, Taiwan (衛生福利部)

Organizers: NHRI (國家衛生研究院) / Centers for Disease Control, Taiwan (疾病管制署)

Co-organizer: Chang Gung Medical Foundation (長庚醫療財團法人) / Chang Gung University (長庚大學) /

National Cheng Kung University (國立成功大學) / National Taiwan University Children Hospital (臺大兒童醫院) /

Taiwan Society of Virology (臺灣病毒學會)

Registration information: From now to September 10 (Online registration)

<https://eva71.nhri.org.tw/>

Contact information: Mr. Chen. (037)246-166#35508 E-mail: cyt@nhri.org.tw



September 28, 2018

Time	Topics	Speaker
09:00-09:10	Opening Enterovirus epidemics and control	
September 28, 2018		
09:10-09:40	Keynote speech I: Enterovirus A71 research in Taiwan: review and implications	Dr. Tzou-Yien Lin (林奏延) NHRI, Taiwan
09:40-10:10	Keynote speech II: Enterovirus epidemiology in the United States: surveillance overview and recent EV-D68 and EV-A71 activity	Dr. John Watson US. CDC
10:10-10:40	Enterovirus surveillance, preparedness, and response in Taiwan	Dr. Philip Lo (羅一鈞) Centers for Disease Control, Taiwan
10:40-11:00	Group photo and Break	
Pathogenesis and virulence of EV-A71		
11:00-11:20	Immunopathogenesis of severe EV-A71 infections	Dr. Ching-Chuan Liu (劉清泉) NCKUH, Taiwan
11:20-11:35	Pathogenesis of acute heart failure in patients with enterovirus 71 rhombencephalitis	Dr. Yun-Ching Fu (傅雲慶) CMUHC, Taiwan
11:35-11:50	Management of EV-A71 patients with cardiopulmonary failure	Dr. Shao-Hsuan Hsia (夏紹軒) CGMH, Taiwan
11:50-12:10	Genetic evolution of EV-A71: impacts on antigenicity and virulence	Dr. Jen-Ren Wang (王貞仁) NCKU, Taiwan
12:10-13:30	Lunch	
Neurological and immune response to EV-A71		
13:30-13:50	Acute neurological complications of EV-A71 infection in Taiwan	Dr. Chao-Ching Huang (黃朝慶) TMU, Taiwan
13:50-14:10	EV-A71 seroepidemiology study in Taiwan and long-term neurological, and psychiatric outcome after CNS involvement	Dr. Luan-Yin Chang (張鑾英) NTUH, Taiwan
14:10-14:20	Humoral immune response to acute EV-A71 infection	Dr. Kuan-Ying Arthur Huang (黃冠穎) CGMH, Taiwan
14:20-14:30	TLR defect in children with severe EV-A71 infection	Dr. Cheng-Lung Ku (顧正峯) CGU, Taiwan
EV-A71 vaccine development		
14:30-14:45	EV-A71 vaccine development in Taiwan	Dr. Jen-Ron Chiang (江正榮) CDC, Taiwan Dr. Chia-Chyi Liu (劉家齊) NHRI, Taiwan
14:45-15:00	EV-A71 vaccine development in China Mainland	Dr. Zhong Huang (黃忠) Institut Pasteur of Shanghai, Chinese Academy of Sciences, China
15:00-15:10	Clinical development of the first bioreactor-generated pediatric Enterovirus 71 vaccine	Dr. Chin-Fan Yang (楊青芬) Enimmune, Taiwan
15:10-15:20	EV-A71 vaccine clinical trial in Taiwan	Dr. Kathy Tai (戴伊晨) Medigen, Taiwan
15:20-15:30	Mucosal viral-vector vaccines in study and prevention of enterovirus infection	Dr. Yen-Hung Chow (周彥宏) NHRI, Taiwan
15:30-15:40	Anti-enterovirus A71 inhibitors: current status and future perspectives.	Dr. Jim-Tong Horng (洪錦堂) CGU, Taiwan
15:40-16:00	Break	
Enteroviruses in Asia-Pacific regions		
16:00-16:15	Human enterovirus 71 disease in Malaysia	Dr. Mong How Ooi Hospital Umum Sarawak, Malaysia
16:15-16:30	An overview of the OLICRU research programme on HFMD and EV-A71 in Vietnam	Dr. Rogier van Doorn Oxford University Clinical Research Unit, Vietnam
16:30-16:45	Current situation of enterovirus infection in Thailand	Dr. Yong Poovorawan Chulalongkorn University, Thailand
16:45-17:00	Molecular epidemiology of human enterovirus 71 in Cambodia	Dr. Veasna Duong Institut Pasteur de Cambodge, Cambodia
17:00-17:15	Establishment of Asia-Pacific Network for Enterovirus Surveillance (APNES)	Dr. Ming-Shi Lee (李敏西) NHRI, Taiwan
17:15-17:30	Q&A	
September 29, 2018		
Time	Topics	Speaker
EV-D68 outbreaks and management		
09:00-09:30	The emergence of Enterovirus-D68	Dr. Mark Abzug Children's Hospital Colorado, USA
09:30-10:00	An outbreak of enterovirus D68 in August–December 2015 in Japan as an emerging “neurovirulent” enterovirus infection	Dr. Hiroyuki Shimizu National Institute of Infectious Diseases, Japan
10:00-10:15	Break	
Other enterovirus infections and future prospects		
10:15-10:30	Enterovirus infection in neonates	Dr. Yhu-Chering Huang (黃玉成) CGMH, Taiwan
10:30-10:50	Future prospects of enterovirus prevention and control	Dr. Shin-Ru Shih (施信如) CGU, Taiwan
10:50-11:10	Q&A	
11:10-12:00	Comprehensive Group Discussion	Dr. Tzou-Yien Lin(林奏延) NHRI, Taiwan
12:30-14:00	Satellite Lunch Meeting	

